D-0297-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0297-2021 was initiated by Teva Pharmaceuticals USA on February 15, 2021 and is designated Class II. Reason for recall: Chemical contamination; Unknown brown residue adhering to the inside of one vial. The recall status is terminated (terminated August 26, 2021). Affected quantity: 9,452 cartons.

Recall Details

Product Type
Drugs
Report Date
March 10, 2021
Initiation Date
February 15, 2021
Termination Date
August 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
9,452 cartons

Product Description

Metoclopramide Injection USP, 10 mg/2 mL (5 mg/mL), 25x2mL Single Dose Vials, Rx only, Distributed by Teva Pharmaceuticals, USA, Inc., Parsippany, NJ Vial NDC 0703-4502-01 (vial) NDC# 0703-4502-04 (tray)

Reason for Recall

Chemical contamination; Unknown brown residue adhering to the inside of one vial.

Distribution Pattern

Nationwide, including Puerto Rico

Code Information

Lot # 31325335B, exp. date 07/2021